
[Bio USA] Samsung Biologics doubles down on CDMO leadership after biosimilar spinoff
CEO John Rim says Bioepis separation unlocks transparency, enhances investor clarity, sharpens strategic focus BOSTON — Samsung Biologics CEO John Rim unveiled an ambitious road map to strengthen the company’s position as a global leader in CDMO during a …